GlassScriptPhysician profile
Oleg Karpenko
NPI 1770883415
$1,336.63
in general payments reported to CMS, 2019-2025
11 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.07 · 2021: $85.02 · 2022: $399 · 2023: $230 · 2024: $141 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $476.99 | 2019-2025 | Collagenase Santyl, Grafix Pl, Regranex |
| Stryker Corporation | $167.33 | 2025 | Citrefix, Prostep Mica, Easyfuse |
| Grt US Holding, INC. | $157.98 | 2021-2022 | |
| Averitas Pharma INC. | $128.40 | 2023-2025 | Qutenza |
| Aroa Biosurgery Incorporated | $109.44 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $94.18 | 2024-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $57.86 | 2019 | |
| Nevro Corp. | $55.72 | 2022 | |
| Horizon Therapeutics Plc | $46.77 | 2021 | |
| Kerecis Limited | $25.69 | 2022 | |
| Amgen INC. | $16.27 | 2024 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oleg Karpenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.